Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials

被引：52

作者：

Choi, I. ^{[2
]}

Tanosaki, R. ^{[3
]}

Uike, N. ^{[2
]}

Utsunomiya, A. ^{[4
]}

Tomonaga, M. ^{[5
]}

Harada, M. ^{[6
]}

Yamanaka, T.

Kannagi, M. ^{[7
]}

Okamura, J. ^{[1
]}

机构：

[1] Kyushu Natl Canc Ctr, Inst Clin Res, Minami Ku, Fukuoka 8111395, Japan

[2] Kyushu Natl Canc Ctr, Dept Hematol, Fukuoka 8111395, Japan

[3] Natl Canc Ctr, Stem Cell Transplantat Unit, Tokyo, Japan

[4] Imamura Bun In Hosp, Dept Hematol, Kagoshima, Japan

[5] Nagasaki Univ, Mol Med Unit, Dept Hematol, Atom Bomb Dis Inst,Sch Med, Nagasaki 852, Japan

[6] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan

[7] Tokyo Med & Dent Univ, Div Med Res, Dept Immunotherapeut, Tokyo, Japan

来源：

BONE MARROW TRANSPLANTATION | 2011年 / 46卷 / 01期

基金：

日本学术振兴会;

关键词：

adult T-cell leukemia/lymphoma; allogeneic hematopoietic SCT; reduced-intensity conditioning regimen; HTLV-1 proviral load; RETROSPECTIVE ANALYSIS; LEUKEMIA-LYMPHOMA; TRANSPLANTATION; INTENSITY; IMPACT;

D O I：

10.1038/bmt.2010.92

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

We have previously conducted clinical trials of allogeneic hematopoietic SCT with reduced-intensity conditioning regimen (RIC) for adult T-cell leukemia/lymphoma (ATLL)-a disease caused by human T-lymphotropic virus type 1 (HTLV-1) infection and having a dismal prognosis. Long-term follow-up studies of these trials revealed that 10 of the 29 patients have survived for a median of 82 months (range, 54-100 months) after RIC, indicating a possible curability of the disease by RIC. However, we have also observed that the patterns of post-RIC changes in HTLV-1 proviral load over time among the 10 survivors were classified into three patterns. This is the first report to clarify the long-term outcomes after RIC for ATLL patients. Bone Marrow Transplantation (2011) 46, 116-118; doi:10.1038/bmt.2010.92; published online 19 April 2010

引用

页码：116 / 118

页数：3

共 50 条

[21] Diagnosis and management of adult T-cell leukemia/lymphoma
Ishitsuka, Kenji
SEMINARS IN HEMATOLOGY, 2021, 58 (02) : 114 - 122
[22] Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP
Bazarbachi, A.
Cwynarski, K.
Boumendil, A.
Finel, H.
Fields, P.
Raj, K.
Nagler, A.
Mohty, M.
Sureda, A.
Dreger, P.
Hermine, O.
BONE MARROW TRANSPLANTATION, 2014, 49 (10) : 1266 - 1268
[23] Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma
Kato, Koji
Akashi, Koichi
VIRUSES-BASEL, 2015, 7 (12): : 6604 - 6612
[24] Current Management of Adult T-Cell Leukemia/Lymphoma
Tobinai, Kensei
ONCOLOGY-NEW YORK, 2009, 23 (14): : 1250 - 1256
[25] Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma
Ureshino, Hiroshi
Kamachi, Kazuharu
Kimura, Shinya
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (06) : 326 - 331
[26] Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma
Utsunomiya, Atae
FRONTIERS IN MICROBIOLOGY, 2019, 10
[27] T-cell lymphoma of the penis as the first manifestation of adult T-cell lymphoma/leukemia
Terada, Tadashi
Shirakashi, Yusuke
Sugiura, Makoto
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2012, 51 (08) : 973 - 975
[28] ADULT T-CELL LEUKEMIA LYMPHOMA IN AN ABORIGINE
KIRKLAND, MA
FRASCA, J
BASTIAN, I
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1991, 21 (05): : 739 - 741
[29] Lenalidomide in Adult T-Cell Leukemia/Lymphoma
Mehta-Shah, Neha
Horwitz, Steven M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4066 - +
[30] Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation
Tokunaga, Masahito
Uto, Hirofumi
Takeuchi, Shogo
Nakano, Nobuaki
Kubota, Ayumu
Tokunaga, Mayumi
Takatsuka, Yoshifusa
Seto, Masao
Ido, Akio
Utsunomiya, Atae
LEUKEMIA & LYMPHOMA, 2017, 58 (01) : 37 - 44

← 1 2 3 4 5 →